Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
Jobst C. von Einem(Ludwig-Maximilians-Universität München), Dominik Paul Modest(Berliner Hochschule für Technik), Sebastian Stintzing(Humboldt-Universität zu Berlin), Volker Heinemann(LMU Klinikum), Thomas Decker, Michael Haas(Harvard University), Stefan Boeck(German Cancer Research Center), Philipp Aubele(Institut für Urheber- und Medienrecht), Julian Walter Holch(Ludwig-Maximilians-Universität München), Martina Stauch, Ursula Vehling‐Kaiser(University of Applied Sciences Landshut), Swantje Held(AIO Studien gGmbH), Andreas Jung(Ludwig-Maximilians-Universität München), Marlies Michl(LMU Klinikum), Clemens Gießen, Stefan Klein(Praxis für Hämatologie und Onkologie), Ludwig Fischer von Weikersthal(Praxis für Hämatologie und Onkologie), Thomas Kirchner(Friedrich-Alexander-Universität Erlangen-Nürnberg), Christoph Schulz, Holger G. Hass(Paracelsus-Kliniken)
Cited by 112
Related Papers
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i>Wild-Type Metastatic Colorectal Cancer
|JAMA Oncology|2016|722
β-Catenin Regulates the Expression of the Matrix Metalloproteinase-7 in Human Colorectal Cancer
|American Journal Of Pathology|1999|663
The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials
|European Journal of Cancer|2016|533